MRNA vaccine for recurrent high-grade glioma
Part of Cancer clinical trials.
This trial tests a new mRNA vaccine for people with a type of brain tumor called high-grade glioma that has come back or progressed. The vaccine is designed to help your immune system recognize and attack the tumor cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a high-grade glioma (WHO Grade 3 or 4) that has come back or gotten worse after standard treatment.
- Your tumor must have one of these specific gene changes: H3.3K27M, H3.1K27M, H3.3G34R, BRAF V600E, PIK3CA H1047R, IDH1 R132H, or EGFRvIII.
- You are at least 16 years old and in generally good health (kidney, liver, heart, and blood counts are within safe limits).
- You are not taking high doses of steroids (dexamethasone ≤2 mg/day) and do not have a severe infection or other active cancer.
- You agree to use effective birth control if you could become pregnant or father a child, for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called NRG-103 for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard treatments. The goal is to see if it's safe and if it might help shrink the tumor.
This early-stage study tests a personalized cancer vaccine designed to prevent glioblastoma (a serious brain tumor) from coming back after surgery and standard treatment. The vaccine aims to train your immune system to recognize and attack any remaining cancer cells.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This trial tests a personalized vaccine created by AI to target your specific brain tumor. It is for people with a glioma that came back after standard treatments like surgery, radiation, or chemotherapy, and whose tumor has enough genetic mutations to make the vaccine.
This Phase 1 trial studies an “RNA-lipid particle” vaccine given after surgery for certain newly diagnosed brain cancers (glioblastoma in adults, high-grade glioma in children/teens). The goal is to see whether the vaccine is safe and can train the immune system to fight the tumor.
This trial tests an experimental 'vaccine' made from your own immune cells (dendritic cells). The vaccine is designed to train your immune system to attack the brain tumor. It is for people whose glioblastoma has returned or progressed after standard treatment.
Hear when a new Glioma, High Grade trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.